Literature DB >> 6378107

An immunohistological study of secondary Sjögren's syndrome.

D A Isenberg, D Rowe, A Tookman, A Hopp, M Griffiths, E Paice, J Stewart, P C Beverley.   

Abstract

The labial biopsies from 13 patients with secondary Sjögren's syndrome (SS) and four disease controls were examined with a panel of monoclonal antibodies to human leucocyte antigens. Large numbers of T cells were found in most of the biopsies. In seven SS patients the T helper/inducer subset was found to be predominant. Antibody to HLA class I antigens consistently stained leucocytes, but other cell types stained more variably. Although the staining with antibody to HLA class II antigen was often weak, approximately as many cells stained with this antibody as with an antileucocyte antibody, implying that the T cells were activated. Anti-IgD revealed membrane staining of a corona of IgD-positive cells in structures resembling germinal centres. Isolated cells throughout the sections also showed strong cytoplasmic staining with anti-IgD. These results suggest a role for T-cell-dependent local antibody synthesis in the pathogenesis of the disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6378107      PMCID: PMC1001372          DOI: 10.1136/ard.43.3.470

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  17 in total

1.  A statistical aid to the diagnosis of keratoconjunctivitis sicca.

Authors:  J A Anderson; K Whaley; J Williamson; W W Buchanan
Journal:  Q J Med       Date:  1972-04

2.  Labial salivary gland biopsy in Sjögren's disease.

Authors:  D M Chisholm; D K Mason
Journal:  J Clin Pathol       Date:  1968-09       Impact factor: 3.411

Review 3.  Sjögren's syndrome. A review with emphasis on immunological features.

Authors:  R Manthorpe; K Frost-Larsen; H Isager; J U Prause
Journal:  Allergy       Date:  1981-04       Impact factor: 13.146

4.  Salivary gland immunoglobulin and rheumatoid factor synthesis in Sjögren's syndrome. Natural history and response to treatment.

Authors:  L G Anderson; N A Cummings; R Asofsky; M B Hylton; T M Tarpley; T B Tomasi; R O Wolf; G L Schall; N Talal
Journal:  Am J Med       Date:  1972-10       Impact factor: 4.965

5.  Immunoglobulin synthesis by salivary gland lymphoid cells in Sjögren's syndrome.

Authors:  N Talal; R Asofsky; P Lightbody
Journal:  J Clin Invest       Date:  1970-01       Impact factor: 14.808

6.  IgA rheumatoid factor in the sera and saliva of patients with rheumatoid arthritis and Sjögren's syndrome.

Authors:  J V Dunne; D A Carson; H L Spiegelberg; M A Alspaugh; J H Vaughan
Journal:  Ann Rheum Dis       Date:  1979-04       Impact factor: 19.103

7.  Alterations in immunoregulatory T cell subsets in active systemic lupus erythematosus.

Authors:  C Morimoto; E L Reinherz; S F Schlossman; P H Schur; J A Mills; A D Steinberg
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

8.  Sjögren's syndrome terminating as a myeloproliferative disorder.

Authors:  W E DeCoteau; S B Katakkar; L Skinnider; R C Hayton; E A Somerville
Journal:  J Rheumatol       Date:  1975-09       Impact factor: 4.666

9.  Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man.

Authors:  J A Ledbetter; R L Evans; M Lipinski; C Cunningham-Rundles; R A Good; L A Herzenberg
Journal:  J Exp Med       Date:  1981-02-01       Impact factor: 14.307

View more
  16 in total

1.  Relation between antinuclear antibodies and the autoimmune rheumatic diseases and disease type and activity in systemic lupus erythematosus using a variety of cultured cell lines.

Authors:  J Sequi; I Leigh; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1991-03       Impact factor: 19.103

2.  HLA class I and II, interferon, interleukin 2, and the interleukin 2 receptor expression on labial biopsy specimens from patients with Sjögren's syndrome.

Authors:  D Rowe; M Griffiths; J Stewart; D Novick; P C Beverley; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1987-08       Impact factor: 19.103

3.  Epithelial HLA-DR expression and T lymphocyte subsets in salivary glands in Sjögren's syndrome.

Authors:  G Lindahl; E Hedfors; L Klareskog; U Forsum
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

Review 4.  Rheumatological manifestations of haematological diseases.

Authors:  S Menon; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

5.  Analysis of antibodies to RNA in patients with systemic lupus erythematosus and other autoimmune rheumatic diseases.

Authors:  F Blanco; J Kalsi; D A Isenberg
Journal:  Clin Exp Immunol       Date:  1991-10       Impact factor: 4.330

6.  Decrease of blood dendritic cells and increase of tissue-infiltrating dendritic cells are involved in the induction of Sjögren's syndrome but not in the maintenance.

Authors:  Y Ozaki; T Ito; Y Son; H Amuro; K Shimamoto; H Sugimoto; Y Katashiba; M Ogata; R Miyamoto; N Murakami; R Amakawa; S Fukuhara
Journal:  Clin Exp Immunol       Date:  2009-12-14       Impact factor: 4.330

7.  Increased epithelial expression of HLA-DQ and HLA-DP molecules in salivary glands from patients with Sjögren's syndrome compared with obstructive sialadenitis.

Authors:  P S Thrane; T S Halstensen; H R Haanaes; P Brandtzaeg
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

8.  Idiopathic myositis: a rheumatological view.

Authors:  M R Ehrenstein; M L Snaith; D A Isenberg
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

9.  Serological and genetic characterization of a human monoclonal immunoglobulin G anti-DNA idiotype.

Authors:  M R Ehrenstein; C M Longhurst; D S Latchman; D A Isenberg
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

10.  Sialadenitis in the MRL-l mouse: morphological and immunohistochemical characterization of resident and infiltrating cells.

Authors:  R Jonsson; A Tarkowski; K Bäckman; R Holmdahl; L Klareskog
Journal:  Immunology       Date:  1987-04       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.